Foundations, promises and uncertainties of personalized medicine.

Personalized medicine introduces the promise to use molecular markers that signal the risk of disease or its presence before clinical signs and symptoms appear. This information underlies a new healthcare strategy focused on prevention and early intervention, rather than reaction to advanced stages of disease. Such a strategy can delay disease onset or minimize symptom severity. The molecular foundations that enable personalized medicine include detection of variation in nucleotide sequence of genes and in characteristic patterns of gene expression, proteins and metabolites. Genetic and molecular patterns are correlated with disease manifestations, drug responses, treatment prognosis, or prediction of predisposition to future disease states. However, the uncertainties for personalized medicine are considerable, including economic, ethical, legal, and societal questions. Although much of its promise remains unproven to date, the foundations of personalized medicine appear solid and evidence is accumulating rapidly pointing to its growing importance in healthcare (Fig. 1).

[1]  Urs A. Meyer,et al.  Pharmacogenetics – five decades of therapeutic lessons from genetic diversity , 2004, Nature Reviews Genetics.

[2]  R. Weinshilboum Inheritance and drug response. , 2003, The New England journal of medicine.

[3]  M. Campiglio,et al.  Biologic and therapeutic role of HER2 in cancer , 2003, Oncogene.

[4]  Geoffrey B. Nilsen,et al.  Whole-Genome Patterns of Common DNA Variation in Three Human Populations , 2005, Science.

[5]  Kathryn A. Phillips,et al.  Measuring the value of pharmacogenomics , 2005, Nature Reviews Drug Discovery.

[6]  R. Weinshilboum,et al.  Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions , 2006, Oncogene.

[7]  D. McHale,et al.  Pharmacogenomics and the Drug Discovery Pipeline , 2005 .

[8]  M. Cronin,et al.  Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Rongwei Fu,et al.  Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force , 2005, Annals of Internal Medicine.

[10]  Toshihiro Tanaka The International HapMap Project , 2003, Nature.

[11]  Gary H Lyman,et al.  Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. , 2005, The American journal of managed care.

[12]  Gudmundur A. Thorisson,et al.  The International HapMap Project Web site. , 2005, Genome research.

[13]  M. McCarthy,et al.  An evaluation of HapMap sample size and tagging SNP performance in large-scale empirical and simulated data sets , 2005, Nature Genetics.

[14]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[15]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[16]  Julie A. Johnson,et al.  Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. , 2005, Pharmacogenetics and genomics.

[17]  Randall Pruim,et al.  Tag SNP selection for Finnish individuals based on the CEPH Utah HapMap database , 2006, Genetic epidemiology.

[18]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[19]  E. Lander,et al.  Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results , 1995, Nature Genetics.

[20]  P. Donnelly,et al.  The effects of human population structure on large genetic association studies , 2004, Nature Genetics.

[21]  K. Adams,et al.  β‐adrenergic Receptor Polymorphisms and Responses during Titration of Metoprolol Controlled Release/extended Release in Heart Failure , 2005, Clinical pharmacology and therapeutics.

[22]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[23]  N. Risch,et al.  The importance of race and ethnic background in biomedical research and clinical practice. , 2003, The New England journal of medicine.

[24]  R. Millikan,et al.  Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. , 2005, Journal of the National Cancer Institute.

[25]  Elad Ziv,et al.  Human population structure and genetic association studies. , 2003, Pharmacogenomics.